Real-world data on managing patients with coronary artery disease and multifocal atherosclerosis. Results of the 12-month international clinical registry of patients with identified multifocal atherosclerosis in the Russian Federation and Eurasian countries (KAMMA)
https://doi.org/10.15829/1560-4071-2025-6152
EDN: MBFXKR
Abstract
Aim. To study real-world data on managing patients with coronary artery disease (CAD) and multifocal atherosclerosis (MFA) for 12 months by outpatient cardiologists.
Material and methods. KAMMA is a real-world registry organized by the Eurasian Association of Therapists. The main branch included men and women over 18 years of age with confirmed atherosclerosis in two or more arterial systems and one or more risk factors for atherosclerosis. The start date for patient recruitment was February 1, 2022 and the end date was November 27, 2022. The design included 3 following visits: 1 — baseline, 2 — after 6 months, 3 — after 12 months. Twentyeight research centers were located in 7 federal districts of the Russian Federation, as well as in the Republics of Kazakhstan, Uzbekistan and Belarus.
Results. A patient population (n=2905) was formed, all of whom had verified CAD. The mean age was 66,0 [59,0; 72,0] years (men — 60,3%). Low-density lipoprotein cholesterol decreased by 20,4% over 12 months, while non-high-density lipoprotein cholesterol — by 12,7%. Over 12 months, lipid-lowering therapy did not undergo significant changes. Statin monotherapy was maintained in 83%, of which only 53,7% of patients received high-dose therapy. Combined statin+ezetimibe therapy was used in 12,4%, while statin+ezetimibe+PCSK9 inhibitor — in 4,6%. During the 1-year follow-up, antithrombotic therapy was not enhanced. Low prescription rate of combination therapy with antiplatelet agents (15,7%) and low-dose rivaroxaban and acetylsalicylic acid (7,9%) remained. By the follow-up end, a high incidence of major adverse cardiovascular events (8,8%) was registered in patients included in the KAMMA registry.
Conclusion. Despite the fact that patients with MFA have a very high cardiovascular risk, routine management of these patients is characterized by high clinical inertia. During the 1-year follow-up, lipid-lowering and antithrombotic therapy was not properly strengthened, due to which the target levels of key lipid profile parameters were not achieved and a high rate of major adverse cardiovascular events was observed in patients included in the registry.
About the Authors
G. P. ArutyunovRussian Federation
Moscow
Competing Interests:
нет
E. I. Tarlovskaya
Russian Federation
Moscow
Nizhny Novgorod
A. G. Arutyunov
Russian Federation
Moscow
Yerevan
Competing Interests:
нет
T. I. Batluk
Russian Federation
Moscow
Competing Interests:
нет
N. A. Koziolova
Russian Federation
Perm
Competing Interests:
нет
A. I. Chesnikova
Russian Federation
Rostov-on-Don
Competing Interests:
нет
A. Y. Vaskin
Russian Federation
Moscow
Competing Interests:
нет
D. S. Tokmin
Russian Federation
Moscow
Competing Interests:
нет
I. G. Bakulin
Russian Federation
St. Petersburg
Competing Interests:
нет
O. L. Barbarash
Russian Federation
Kemerovo
Competing Interests:
нет
N. Y. Grigoryeva
Russian Federation
Nizhny Novgorod
Competing Interests:
нет
I. V. Gubareva
Russian Federation
Samara
Competing Interests:
нет
N. V. Izmozherova
Russian Federation
Yekaterinburg
Competing Interests:
нет
U. R. Kamilova
Uzbekistan
Tashkent
Competing Interests:
нет
S. G. Kechedzhieva
Russian Federation
Stavropol
Competing Interests:
нет
Z. F. Kim
Russian Federation
Kazan
Competing Interests:
нет
N. A. Koriagina
Russian Federation
Perm
Competing Interests:
нет
S. V. Mironova
Russian Federation
Perm
Competing Interests:
нет
N. P. Mitkovskaya
Belarus
Minsk
Competing Interests:
нет
S. V. Nemirova
Russian Federation
Nizhny Novgorod
Competing Interests:
нет
L. M. Nurieva
Russian Federation
Kazan
Competing Interests:
нет
M. M. Petrova
Russian Federation
Krasnoyarsk
Competing Interests:
нет
E. A. Polyanskaya
Russian Federation
Perm
Competing Interests:
нет
A. P. Rebrov
Russian Federation
Saratov
Competing Interests:
нет
A. V. Svarovskaya
Russian Federation
Tomsk
Competing Interests:
нет
E. A. Smirnova
Russian Federation
Ryazan
Competing Interests:
нет
A. B. Sugraliev
Kazakhstan
Almaty
Competing Interests:
нет
Y. B. Khovaeva
Russian Federation
Perm
Competing Interests:
нет
G. V. Shavkuta
Russian Federation
Rostov-on-Don
Competing Interests:
нет
I. I. Shaposhnik
Russian Federation
Chelyabinsk
Competing Interests:
нет
G. T. Aimakhanova
Kazakhstan
Almaty
Competing Interests:
нет
M. Y. Alieva
Uzbekistan
Tashkent
Competing Interests:
нет
A. B. Almukhanova
Kazakhstan
Almaty
Competing Interests:
нет
A. V. Aparkina
Russian Federation
Saratov
Competing Interests:
нет
D. A. Akhmentaeva
Kazakhstan
Almaty
Competing Interests:
нет
R. A. Bashkinov
Russian Federation
Moscow
St. Petersburg
Competing Interests:
нет
N. M. Bekisheva
Kazakhstan
Almaty
Competing Interests:
нет
L. N. Belousova
Russian Federation
St. Petersburg
Competing Interests:
нет
E. I. Blokhina
Russian Federation
Nizhny Novgorod
Competing Interests:
нет
V. O. Bochkareva
Russian Federation
Krasnoyarsk
Competing Interests:
нет
M. V. Buianova
Russian Federation
Nizhny Novgorod
Competing Interests:
нет
F. Y. Valikulova
Russian Federation
Nizhny Novgorod
Competing Interests:
нет
A. D. Vende
Russian Federation
Tomsk
Competing Interests:
нет
A. S. Galyavich
Russian Federation
Kazan
Competing Interests:
нет
V. V. Genkel
Russian Federation
Chelyabinsk
Competing Interests:
нет
E. V. Gorbunova
Russian Federation
Kemerovo
Competing Interests:
нет
E. D. Gordeychuk
Russian Federation
Moscow
Competing Interests:
нет
E. A. Grigorenko
Belarus
Minsk
Competing Interests:
нет
E. V. Grigoryeva
Russian Federation
Saratov
Competing Interests:
нет
G. M. Dabylova
Kazakhstan
Almaty
Competing Interests:
нет
I. L. Davydkin
Russian Federation
Samara
Competing Interests:
нет
D. S. Evdokimov
Russian Federation
St. Petersburg
Competing Interests:
нет
A. N. Ermilova
Russian Federation
Moscow
Competing Interests:
нет
S. B. Zhangelova
Kazakhstan
Almaty
Competing Interests:
нет
N. V. Zhdankina
Russian Federation
Nizhny Novgorod
Competing Interests:
нет
E. I. Zheleznyak
Russian Federation
Rostov-on-Don
Competing Interests:
нет
N. S. Ilyanok
Russian Federation
Ryazan
Competing Interests:
нет
D. A. Kapsultanova
Kazakhstan
Almaty
Competing Interests:
нет
N. A. Karoli
Russian Federation
Saratov
Competing Interests:
нет
E. A. Kartashova
Russian Federation
Rostov-on-Don
Competing Interests:
нет
A. S. Kuznetsova
Russian Federation
Chelyabinsk
Competing Interests:
нет
A. T. Kumaritova
Russian Federation
St. Petersburg
Competing Interests:
нет
N. A. Magdeeva
Russian Federation
Saratov
Competing Interests:
нет
S. A. Makarov
Russian Federation
Kemerovo
Competing Interests:
нет
O. A. Mamadaliev
Kazakhstan
Almaty
Competing Interests:
нет
E. S. Melnikov
Russian Federation
Moscow
St. Petersburg
Competing Interests:
нет
N. J. Musrepov
Kazakhstan
Almaty
Competing Interests:
нет
R. Ya. Namatova
Kazakhstan
Almaty
Competing Interests:
нет
M. V. Novikova
Russian Federation
Stavropol
Competing Interests:
нет
I. A. Obukhova
Russian Federation
Krasnoyarsk
Competing Interests:
нет
E. V. Ponomarenko
Russian Federation
Krasnodar
Competing Interests:
нет
A. O. Rubanenko
Russian Federation
Samara
O. A. Rubanenko
Russian Federation
Samara
Competing Interests:
нет
V. A. Safronenko
Russian Federation
Rostov-on-Don
E. I. Suchkova
Russian Federation
Ryazan
Competing Interests:
нет
A. I. Sycheva
Perm
Competing Interests:
нет
D. R. Tagaeva
Uzbekistan
Tashkent
Competing Interests:
нет
M. A. Trubnikova
Russian Federation
Moscow
Sochi
Competing Interests:
нет
T. P. Trunina
Russian Federation
Ryazan
Competing Interests:
нет
S. A. Tynalieva
Kazakhstan
Almaty
Competing Interests:
нет
A. G. Frolov
Russian Federation
Nizhny Novgorod
Competing Interests:
нет
V. V. Khatlamadzhiyan
Russian Federation
Rostov-on-Don
Competing Interests:
нет
Y. I. Khokhlova
Russian Federation
St. Petersburg
Competing Interests:
нет
A. I. Chernyavina
Russian Federation
Perm
Competing Interests:
нет
O. Y. Chizhova
Russian Federation
St. Petersburg
Competing Interests:
нет
M. A. Shambatov
Russian Federation
Yekaterinburg
Competing Interests:
нет
T. V. Shnyukova
Russian Federation
Rostov-on-Don
Competing Interests:
нет
Y. V. Shchukin
Russian Federation
Samara
References
1. Mazzolai L, Teixido-Tura G, Lanzi S, et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases: Developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM), European Heart Journal, 2024:ehae179. doi: 10.1093/eurheartj/ehae179.
2. Arutyunov GP, Tarlovskaya EI, Arutyunov AG, et al. Peculiarities of polyvascular disease and the diagnostic significance of the ankle-brachial index in patients with coronary artery disease: results from the real-world registry KAMMA (Clinical registry on patient population with polyvascular disease in the Russian Federation and Eurasian countries). Russian Journal of Cardiology. 2024;29(4):5837. (In Russ.) doi: 10.15829/1560-4071-2024-5837.
3. Costa C, Riquito B, Perdigão S, et al. Undercover Peripheral Arterial Disease. Cureus. 2024;16(1):e51590. doi:10.7759/cureus.51590.
4. Bonaca MP, Nault P, Giugliano RP, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137(4):338-50. doi:10.1161/CIRCULATIONAHA.117.032235.
5. Anand SS, Aboyans V, Bosch J, et al.; XATOA Steering Committee. Identifying the highest risk vascular patients: Insights from the XATOA registry. Am Heart J. 2024;269:191-200. doi: 10.1016/j.ahj.2024.01.001.
6. Ray KK, Haq I, Bilitou A, et al.; SANTORINI Study Investigators. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624. doi:10.1016/j.lanepe.2023.100624.
7. Hess CN Hess CN, Cannon CP, et al. Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2021;77(24):3016-27. doi: 10.1016/j.jacc.2021.04.060.
8. Hess CN, Daffron A, Nehler MR, et al. Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2024;83:2658-70.
9. Secemsky EA, Carroll BJ, Krawisz AK. The Ongoing Struggle to Optimize Lipid-Lowering Therapy in Patients With PAD: PADdling in Circles. J Am Coll Cardiol. 2021;77(24):3028-30. doi: 10.1016/j.jacc.2021.04.057.
10. Ranger GS, McKinley-Brown C, Rogerson E, Schimp-Manuel K. Aspirin Use, Compliance, and Knowledge of Anticancer Effect in the Community. Perm J. 2020;24:19. doi: 10.7812/TPP/19.116.
11. Ferreira PD Jr, Simoes JA Sr, Velho DC Sr. Adherence to Antihypertensive Therapy and Its Determinants: A Systematic Review. Cureus. 2024;16(5):e59532. doi: 10.7759/cureus.59532.
12. Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) doi: 10.15829/29/1560-4071-2020-4076.
13. Sheth MS, Yu B, Chu A, et al. Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study. J Am Heart Assoc. 2022;11(24):e026553. doi:10.1161/JAHA.122.026553.
14. Lapébie FX, Aboyans V, Lacroix P, et al. Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry. Eur J Vasc Endovasc Surg. 2021;62(3): 439-49. doi: 10.1016/j.ejvs.2021.05.028.
15. Eikelboom JW, Bhatt DL, Fox KAA, et al. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. J Am Coll Cardiol. 2021;78(1):14-23. doi: 10.1016/j.jacc.2021.04.083.
16. Gutierrez JA, Mulder H, Jones WS, et al. Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial. JAMA Netw Open. 2018;1(7):e185239. doi: 10.1001/jamanetworkopen.2018.5239.
Supplementary files
- During the 1-year follow-up, lipid-lowering therapy of patients with coronary artery disease and multifocal atherosclerosis was not properly strengthened, due to which the target levels of key lipid profile parameters were not achieved in the vast majority of patients (low-density lipoprotein cholesterol in 78%, non-high-density lipoprotein cholesterol in 81%).
- During the 1-year follow-up, antithrombotic therapy was not intensified' the low prescription rate of combination therapy with antiplatelet agents (15,7%) and low doses of rivaroxaban and acetylsalicylic acid (7,9%) remained.
- By the end of the 12-month follow-up period, a high rate of major adverse cardiovascular events (8,8%) was registered in patients included in the KAMMA registry.
Review
For citations:
Arutyunov G.P., Tarlovskaya E.I., Arutyunov A.G., Batluk T.I., Koziolova N.A., Chesnikova A.I., Vaskin A.Y., Tokmin D.S., Bakulin I.G., Barbarash O.L., Grigoryeva N.Y., Gubareva I.V., Izmozherova N.V., Kamilova U.R., Kechedzhieva S.G., Kim Z.F., Koriagina N.A., Mironova S.V., Mitkovskaya N.P., Nemirova S.V., Nurieva L.M., Petrova M.M., Polyanskaya E.A., Rebrov A.P., Svarovskaya A.V., Smirnova E.A., Sugraliev A.B., Khovaeva Y.B., Shavkuta G.V., Shaposhnik I.I., Aimakhanova G.T., Alieva M.Y., Almukhanova A.B., Aparkina A.V., Akhmentaeva D.A., Bashkinov R.A., Bekisheva N.M., Belousova L.N., Blokhina E.I., Bochkareva V.O., Buianova M.V., Valikulova F.Y., Vende A.D., Galyavich A.S., Genkel V.V., Gorbunova E.V., Gordeychuk E.D., Grigorenko E.A., Grigoryeva E.V., Dabylova G.M., Davydkin I.L., Evdokimov D.S., Ermilova A.N., Zhangelova S.B., Zhdankina N.V., Zheleznyak E.I., Ilyanok N.S., Kapsultanova D.A., Karoli N.A., Kartashova E.A., Kuznetsova A.S., Kumaritova A.T., Magdeeva N.A., Makarov S.A., Mamadaliev O.A., Melnikov E.S., Musrepov N.J., Namatova R.Ya., Novikova M.V., Obukhova I.A., Ponomarenko E.V., Rubanenko A.O., Rubanenko O.A., Safronenko V.A., Suchkova E.I., Sycheva A.I., Tagaeva D.R., Trubnikova M.A., Trunina T.P., Tynalieva S.A., Frolov A.G., Khatlamadzhiyan V.V., Khokhlova Y.I., Chernyavina A.I., Chizhova O.Y., Shambatov M.A., Shnyukova T.V., Shchukin Y.V. Real-world data on managing patients with coronary artery disease and multifocal atherosclerosis. Results of the 12-month international clinical registry of patients with identified multifocal atherosclerosis in the Russian Federation and Eurasian countries (KAMMA). Russian Journal of Cardiology. 2025;30(3):6152. (In Russ.) https://doi.org/10.15829/1560-4071-2025-6152. EDN: MBFXKR